Hank JA - Search Results

1

The in vitro function of lymphocytes from 25 cancer patients receiving four to seven consecutive days of recombinant IL-2.

Rosenthal NS, Hank JA, Kohler PC, Minkoff DZ, Moore KH, Bechhofer R, Hong R, Storer B, Sondel PM. Rosenthal NS, et al. Among authors: hank ja. J Biol Response Mod. 1988 Apr;7(2):123-39. J Biol Response Mod. 1988. PMID: 3258904

2

Repetitive weekly cycles of recombinant human interleukin-2: responses of renal carcinoma with acceptable toxicity.

Sosman JA, Kohler PC, Hank J, Moore KH, Bechhofer R, Storer B, Sondel PM. Sosman JA, et al. Among authors: hank j. J Natl Cancer Inst. 1988 Mar 2;80(1):60-3. doi: 10.1093/jnci/80.1.60. J Natl Cancer Inst. 1988. PMID: 3257526

3

A direct comparison of immunological and clinical effects of interleukin 2 with and without interferon-alpha in humans.

Schiller JH, Hank J, Storer B, Borchert AA, Moore KH, Albertini M, Bechhofer R, Wesley O, Brown RR, Bastin AM, et al. Schiller JH, et al. Cancer Res. 1993 Mar 15;53(6):1286-92. Cancer Res. 1993. PMID: 8443808 Clinical Trial.

4

Strategies for improving antitumor activity utilizing IL-2: preclinical models and analysis of antitumor activity of lymphocytes from patients receiving IL-2.

Albertini MR, Hank JA, Sondel PM. Albertini MR, et al. Among authors: hank ja. Biotherapy. 1992;4(3):189-98. doi: 10.1007/BF02174205. Biotherapy. 1992. PMID: 1599802 Review. No abstract available.

5

BLT-esterase activity following in vitro and in vivo activation of human lymphocytes with interleukin-2. In vivo IL-2 induces BLT-esterase.

Cannon A, Hank JA, Sondel PM. Cannon A, et al. Among authors: hank ja. Biotherapy. 1991;3(3):253-60. doi: 10.1007/BF02171689. Biotherapy. 1991. PMID: 1854594

6

Prolonged interleukin-2 (IL-2) treatment can augment immune activation without enhancing antitumor activity in renal cell carcinoma.

Sosman JA, Hank JA, Moore KH, Borchert A, Schell K, Kohler PC, Goldstein D, Bechhofer R, Storer B, Albertini MR, et al. Sosman JA, et al. Among authors: hank ja. Cancer Invest. 1991;9(1):35-48. doi: 10.3109/07357909109032798. Cancer Invest. 1991. PMID: 2012995 Review.

7

Depressed in vitro T cell responses concomitant with augmented interleukin-2 responses by lymphocytes from cancer patients following in vivo treatment with interleukin-2.

Hank JA, Sosman JA, Kohler PC, Bechhofer R, Storer B, Sondel PM. Hank JA, et al. J Biol Response Mod. 1990 Feb;9(1):5-14. J Biol Response Mod. 1990. PMID: 2181071 Clinical Trial.

8

Limiting dilution analysis of lymphokine-activated killer cell precursor frequencies in peripheral blood lymphocytes of cancer patients receiving interleukin-2 therapy.

Albertini MR, Oettel KR, Weil-Hillman G, Lindstrom MJ, Schell K, Hank JA, Sondel PM. Albertini MR, et al. Among authors: hank ja. J Biol Response Mod. 1990 Oct;9(5):456-62. J Biol Response Mod. 1990. PMID: 2254758

9

"Lymphokine activated killing" as treatment for human cancer: clinical extrapolations from laboratory studies with interleukin-2 expanded leukocytes.

Sondel PM, Hank JA, Kohler PC, Chen BP, Sosman J. Sondel PM, et al. Among authors: hank ja. Prog Clin Biol Res. 1989;288:151-60. Prog Clin Biol Res. 1989. PMID: 2654949 Review. No abstract available.

10

Prospects for clinical cancer treatment using interleukin-2.

Sondel PM, Hank JA. Sondel PM, et al. Among authors: hank ja. Cancer Invest. 1989;7(5):437-42. doi: 10.3109/07357908909041374. Cancer Invest. 1989. PMID: 2695228 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

163 results

Search Page

Filters